Menu

Recent Interviews

Dirk Graszt, CEO, Clean Logistics SE

Dirk Graszt
CEO | Clean Logistics SE
Trettaustr.32, 21107 Hamburg (DE)

info@cleanlogistics.de

+49-4171-6791300

Interview Clean Logistics: Hydrogen challenge to Daimler + Co.


Matthew Salthouse, CEO, Kainantu Resources

Matthew Salthouse
CEO | Kainantu Resources
3 Phillip Street #19-01 Royal Group Building, 048693 Singapore (SGP)

info@krl.com.sg

+65 6920 2020

Interview Kainantu Resources: "We hold the key to growth in the Asia-Pacific region".


Justin Reid, President and CEO, Troilus Gold Corp.

Justin Reid
President and CEO | Troilus Gold Corp.
36 Lombard Street, Floor 4, M5C 2X3 Toronto, Ontario (CAN)

info@troilusgold.com

+1 (647) 276-0050

Interview Troilus Gold: "We are convinced that Troilus is more than just a mine".


12. October 2021 | 12:32 CET

Defence Therapeutics, BioNTech, Valneva - When will things pick up again?

  • Biotechnology
Photo credits: pixabay.com

Biotechnology companies can experience a significant, sometimes even exponential, increase in value virtually overnight with a new, successful active ingredient. BioNTech is a prime example of this. But not every research effort leads to success, and CureVac shareholders can tell you a thing or two about that. Canada's Defence Therapeutics and Valneva have innovative research pipelines. Where should investors consider investing now?

time to read: 3 minutes by Carsten Mainitz
ISIN: DEFENCE THERAPEUTICS INC | CA24463V1013 , BIONTECH SE SPON. ADRS 1 | US09075V1026 , VALNEVA SE EO -_15 | FR0004056851


 

Author

Carsten Mainitz

The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

About the author


Defence Therapeutics - Further significant progress

Biotechnology Company Defence Therapeutics focuses on therapeutic methods to fight cancer and the development of vaccines against infectious diseases. The Canadians are pursuing an innovative approach based on the proprietary Accum platform. ADC (Antibody Drug Conjugates) preparations are currently being used to develop the next generation of vaccines. This approach is particularly promising for cancer therapy, as it could shorten treatment duration and reduce side effects while increasing efficacy.

The Company has made significant progress in recent months. The developed vaccine, AccuVAC-PT001, showed serum cross-reactivity with the spike protein of several SARS-CoV2 variants in laboratory tests in isolated vaccinated animals. In addition, it showed the highest efficacy with the Delta variant. To strategically optimize clinical trials, the biotechnology Company recently brought on board Biopharma Excellence, a subsidiary of Pharmalex GmbH, a global pharmaceutical consulting firm.

Recently, the Canadians announced completing all necessary steps to prepare for a pre-IND meeting to initiate a Phase I melanoma trial using the Company's dendritic cell (DC)-based cancer vaccine candidate, AccuVAC-D002. According to a Fortune Business Insights report, the skin cancer treatment market is expected to reach approximately USD 15 billion by 2027. If Defence Therapeutics' innovative approach becomes established, the stock has room to run. The market capitalization is currently at CAD 223 million.

BioNTech - Bottoming out?

BioNTech has written an impressive success story in recent months. Alongside the US Company Moderna, the Company has established itself as one of the world's two leading Corona vaccine manufacturers based on so-called mRNA (messenger RNA, ribonucleic acid). In this approach, only a messenger molecule is administered instead of a molecular active ingredient. The messenger challenges the body's immune system to build up an effective defense.

The share price sprinted to a good USD 450 and is currently trading just below the USD 250 mark. The Company is thus valued at around USD 60 billion. Based on average analyst estimates for this and the next fiscal year, the stock is extremely moderately valued with a P/E ratio of about 6 in each case. In our opinion, it is only a matter of time before the share price rises significantly again. The story is intact, and the pandemic will continue to accompany us for some time to come, making regular booster shots necessary. Thus, the current price weakness offers an excellent risk-reward ratio.

Valneva - Theory and practice

In contrast to Moderna and BioNTech, the French-based Company takes an entirely different approach to develop a corona vaccine. Valneva resorts to the method of so-called dead viruses, which has been established for many years. This vaccination method has long been used successfully against hepatitis B, polio, tetanus and diphtheria. The final studies are currently underway, and Valneva expects to receive emergency approval for the vaccine this year. A few weeks ago, the share price came under significant pressure because the British government unexpectedly canceled a previously placed major order. In perspective, the approach with dead viruses has a legitimate chance of success.

Furthermore, vaccination critics who reject the Corona vaccine due to a lack of long-term experience could perhaps be swayed to change their minds in this way. The Company is currently valued at EUR 1.3 billion. Analysts believe in its success and forecast black figures for the next fiscal year, which would give the stock a single-digit P/E ratio at the current price level of around EUR 12.


The biotech stocks presented offer a favorable risk-reward ratio. Whether it is the high flyer BioNTech, whose shares are currently correcting, the turnaround stock Valneva or the innovative Defence Therapeutics is ultimately a matter of taste. If the Canadians make further progress, this should be reflected positively in the share price.


Author

Carsten Mainitz

The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

20. October 2021 | 11:04 CET | by Armin Schulz

Bayer, Sativa Wellness Group, MorphoSys - Can the pharmaceutical industry benefit from the new German government?

  • Biotechnology

The federal election is over, and the pharmaceutical industry has to adjust to the new political constellation. The industry is facing change. Digitization is an important topic. To not lose even more researchers to foreign countries, approval processes must be accelerated and bureaucracy reduced. If we always acted as decisively as we did during the pandemic, much more could be achieved. The new federal government is flirting with the legalization of cannabis. If this were to happen, the market would probably be huge. The next four years promise to be exciting.

Read

18. October 2021 | 10:44 CET | by Nico Popp

BioNTech, Cardiol Therapeutics, Bayer: Where triple-digit returns beckon

  • Biotechnology

The pandemic is drawing to a close. Vaccination rates are high, and a new wave is - fortunately - not picking up speed. But in this environment, what is happening to many highly acclaimed pandemic stocks? Are vaccine manufacturers still interesting at the moment? We look at how the industry is faring and where opportunities can still be found.

Read

14. October 2021 | 11:27 CET | by André Will-Laudien

BioNTech, Cardiol Therapeutics, CureVac: A decade's worth of ideas!

  • Biotechnology

Biotechnology remains a hotly contested industry. In the fight against a wide range of diseases, biopharmaceuticals are the first port of call. It studies the relationship between drugs and excipients' chemical and physical properties and their form of administration in a living organism. By directly applying findings from biology and biochemistry, technically functional elements are identified. The central objectives are to research, improve and develop processes for the production of relevant substances. Often research goes nowhere; we take a look at the sector.

Read